Home  >  Research  >  Labs  >  Cancer Program  >  MELANOMA DISCOVERY

SELECTED PUBLICATIONS

  1. Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen H, Carstam L, Bagge RO, Nilsson LM, Nilsson JA: Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Annals of oncology 2020, 31(2):266-273.
  2. Karlsson J, Nilsson LM, Mitra S, Alsen S, Shelke GV, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindner P, Larsson E, Olofsson Bagge R, Nilsson JA: Molecular profiling of driver events in metastatic uveal melanoma. Nature communications 2020, 11(1):1894.
  3. Hofving T, Karlsson J, Nilsson O, Nilsson JA: H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines. Nature genetics 2019, 51(10):1426-1427.
  4. Forsberg EMV, Lindberg MF, Jespersen H, Alsen S, Bagge RO, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA: HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer research 2019, 79(5):899-904.
  5. Nilsson JA, Olofsson Bagge R, Ny L: Mouse avatars take off as cancer models. Nature 2018, 562(7726):192.
  6. Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson JA, Lowe SW, Reis-Filho JS, Rosen N, Lito P: An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer. Nature medicine 2017, 23(8):929-937.
  7. Jespersen H, Lindberg MF, Donia M, Soderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA: Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature communications 2017, 8(1):707.
  8. Ben-Shabat I, Belgrano V, Ny L, Nilsson JA, Lindner P, Olofsson Bagge R: Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Annals of surgical oncology 2016, 23(4):1327-1334.
  9. Panda S, Nilsson JA, Gekara NO: Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes. Immunity 2015, 43(4):647-659.
  10. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyurek LM, Lindahl P, Nilsson JA, Bergo MO: Antioxidants can increase melanoma metastasis in mice. Science translational medicine 2015, 7(308):308re308.
  11. Fredriksson NJ, Ny L, Nilsson JA, Larsson E: Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature genetics 2014, 46(12):1258-1263.
  12. Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA: BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(26):E2721-2730.
  13. Hoglund A, Nilsson LM, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, Nikolova V, Keller U, Nilsson JA: Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 2011, 17(22):7067-7079.
  14. Hoglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA: Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009, 113(18):4281-4288.
  15. Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL: Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer cell 2005, 7(5):433-444.